Anti‐immunoglobulin E provides an additional therapy to conventional steroids for Kimura's disease

Ao, Suiting; Huang, Gege; Tang, Xuhua; Zhu, Zhe; Han, Jiande; Wang, Fang; Zhai, Wanying

doi:10.1111/1346-8138.17021

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment options for KD include surgical excisions or conservative therapies, such as systemic or intralesional corticosteroids, cytotoxic therapy, or radiotherapy, while the optimal treatment is still controversial. 32 The preferred treatment for this condition has been suggested to be complete surgical excision, with or without corticosteroid therapy. However, in cases where the lesion is large, ill-defined, and systemically involved, achieving complete removal through surgery can often be challenging and recurrence rates tend to be high.…”

Section: Discussionmentioning

confidence: 99%

“…Oral corticosteroids are effective in the treatment of Kimura disease, but patients are more likely to relapse once they stop taking the drug. 10 , 32 , 33 Recurrence rates are various due to the different treatment methods for KD, the recurrence rate was lowest (26.94%) for surgical resection combined with adjuvant therapy, followed by surgical resection alone with an overall recurrence rate of 30.5%. Medical therapy alone had a recurrence rate of 45%, while radiotherapy alone had the highest recurrence rate of 60%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Kimura Disease: A Detailed Analysis of Clinical and Radiological Manifestations in a Retrospective Case Series

Zhao,

Zhou,

Mao

et al. 2024

JIR

View full text Add to dashboard Cite

Background Kimura disease (KD) is a rare chronic inflammatory disease that affects mainly young Asian men and is characterized by painless subcutaneous masses, lymphadenopathy, and elevated serum IgE levels. Despite its benign nature, KD poses a diagnostic and therapeutic challenge due to its rarity and clinical variability. Objective This study aimed to provide a comprehensive analysis of the clinical and radiological features of KD in a retrospective case series, to assess treatment outcomes, and to discuss the implications for diagnosis and management. Methods We retrospectively analyzed four histologically confirmed cases of KD admitted to Zhejiang Provincial People’s Hospital from January 2018 to October 2023. Clinical and radiological data were retrospectively analyzed, and imaging findings were analyzed by two neuroradiologists to determine lesion characteristics and contrast enhancement patterns. Results Our findings showed that the patients were predominantly male, with a mean age of 43 years and an age range of 13–71 years. All patients presented with painless subcutaneous masses and three of them had peripheral blood eosinophilia and elevated serum IgE levels. Radiographically, the lesions were predominantly ill-defined with heterogeneous enhancement, accompanied by subcutaneous fat atrophy. Complete surgical excision and oral corticosteroids were effective treatments, and no recurrence was noted during follow-up. Conclusion KD should be considered in the differential diagnosis of painless subcutaneous masses in the head and neck region, especially in the presence of eosinophilia and elevated IgE levels. Our findings contribute to the understanding of KD’s clinical and radiological spectrum and highlight the need for long-term follow-up due to the risk of recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Kimura Disease: A Detailed Analysis of Clinical and Radiological Manifestations in a Retrospective Case Series

Zhao,

Zhou,

Mao

et al. 2024

JIR

View full text Add to dashboard Cite

show abstract

Efficacy and safety of dupilumab in the treatment of Kimura’s disease

Liu,

Ran,

Zhang

et al. 2024

QJM: An International Journal of Medicine

View full text Add to dashboard Cite

Background Kimura's disease (KD) is a rare chronic inflammatory condition characterized by nodules and lymphadenopathy in the head and neck region, exhibiting type II inflammation. Dupilumab is commonly used against type II inflammation. Aim To evaluate the efficacy and safety of dupilumab in KD patients. Design The real-world study was conducted in a hospital in China. Methods Six male patients with a mean age of 24.50 ± 15.47 years were treated with dupilumab following the same protocol as that for atopic dermatitis (AD). Clinical and laboratory indicators, such as maximum nodule diameter, blood eosinophil count, eosinophil percentage, and total serum IgE levels were assessed at baseline, week 12, and week 24. Adverse events were documented. Paired t-tests and one-way ANOVA were used for statistical analysis. Results The results showed significant reductions in the longest nodule diameter at week 12 (P = 0.008) and week 24 (P = 0.001) compared to baseline. Blood eosinophil count decreased by 57.95% (P = 0.024) at week 12 and 90.59% (P = 0.030) at week 24. Eosinophil percentage decreased by 58.44% (P = 0.026) at week 12 and 89.37% (P = 0.013) at week 24. Total serum IgE levels decreased by 78.02% (P = 0.040) at week 12 and 89.55% (P = 0.031) at week 24. The presence of AD did not affect the results. One patient experienced temporary facial erythema after 32 weeks of treatment, which resolved with topical treatment. No other adverse events were reported. Conclusion Dupilumab demonstrated effectiveness in treating KD without severe adverse events.

show abstract

Kimura’s disease: a mysterious orbital mass

Yadav,

Mishra,

Mehrotra

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

A male patient in his 20s presented with right lower eyelid swelling and occasional eye ache that was first noticed 3 years ago. Ocular examination revealed a palpable orbital mass, proptosis and restriction of right eye movement. The best-corrected visual acuity in the right eye was 6/24. Fundus examination revealed optic disc hyperemia with a blurred disc margin. Rest ocular examination of both eyes was within normal limits. Haematological examination revealed raised TLC, ESR and eosinophilia. MRI showed a relatively well-defined isointense to hypointense lesion showing heterogeneously post-contrast enhancement involving the belly of the inferior rectus muscle of the right eye. FNAC and histopathology confirmed a diagnosis of Kimura’s disease. Oral leflunomide 10 mg/day and prednisolone 40 mg was advised. The swelling started to decrease within 2 weeks of treatment. At 2 months follow-up, the swelling and mass resolved completely and the patient was asymptomatic.

show abstract

Anti‐immunoglobulin E provides an additional therapy to conventional steroids for Kimura's disease

Cited by 4 publications

References 17 publications

Kimura Disease: A Detailed Analysis of Clinical and Radiological Manifestations in a Retrospective Case Series

Kimura Disease: A Detailed Analysis of Clinical and Radiological Manifestations in a Retrospective Case Series

Efficacy and safety of dupilumab in the treatment of Kimura’s disease

Kimura’s disease: a mysterious orbital mass

Contact Info

Product

Resources

About